Smartleaf Asset Management LLC Boosts Stake in Artivion, Inc. (NYSE:AORT)

Smartleaf Asset Management LLC lifted its holdings in Artivion, Inc. (NYSE:AORT) by 236.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,118 shares of the company’s stock after buying an additional 786 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Artivion were worth $32,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the company. Arcadia Investment Management Corp MI purchased a new stake in Artivion during the fourth quarter worth $43,000. New York State Common Retirement Fund boosted its position in Artivion by 2.5% during the fourth quarter. New York State Common Retirement Fund now owns 41,017 shares of the company’s stock worth $1,173,000 after purchasing an additional 1,000 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in Artivion during the fourth quarter worth $78,000. Principal Financial Group Inc. boosted its position in Artivion by 3.8% during the fourth quarter. Principal Financial Group Inc. now owns 202,028 shares of the company’s stock worth $5,776,000 after purchasing an additional 7,398 shares in the last quarter. Finally, Calamos Advisors LLC boosted its position in Artivion by 113.7% during the fourth quarter. Calamos Advisors LLC now owns 63,029 shares of the company’s stock worth $1,802,000 after purchasing an additional 33,541 shares in the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Artivion

In other Artivion news, insider John E. Davis sold 15,100 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total transaction of $356,511.00. Following the completion of the sale, the insider now directly owns 208,778 shares in the company, valued at $4,929,248.58. This represents a 6.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Jean F. Holloway sold 5,335 shares of the company’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $145,698.85. Following the sale, the senior vice president now owns 149,799 shares of the company’s stock, valued at $4,091,010.69. This represents a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 90,799 shares of company stock worth $2,356,223. 8.10% of the stock is currently owned by insiders.

Artivion Stock Performance

Artivion stock opened at $23.58 on Thursday. The firm has a market capitalization of $991.37 million, a P/E ratio of -1,178.85 and a beta of 1.79. The stock has a fifty day moving average price of $28.83 and a 200 day moving average price of $27.77. Artivion, Inc. has a 52 week low of $19.11 and a 52 week high of $32.33. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71.

Artivion (NYSE:AORT) last released its earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). The business had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. Equities research analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current year.

Wall Street Analyst Weigh In

AORT has been the topic of a number of research analyst reports. Needham & Company LLC decreased their target price on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. Stifel Nicolaus decreased their target price on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. Finally, JMP Securities reissued a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.